Humana Inc. (NYSE:HUM) Receives $297.68 Average Target Price from Brokerages

Shares of Humana Inc. (NYSE:HUM) have been given an average rating of “Hold” by the twenty-four ratings firms that are covering the company, MarketBeat reports. Nineteen investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $297.68.

A number of research analysts recently issued reports on the company. Wells Fargo & Company reduced their price objective on Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Barclays boosted their price target on Humana from $253.00 to $255.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 22nd. Morgan Stanley boosted their price target on Humana from $288.00 to $301.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 17th. Piper Sandler boosted their price target on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Finally, Bank of America upgraded Humana from an “underperform” rating to a “neutral” rating and boosted their price target for the stock from $247.00 to $308.00 in a research report on Wednesday, November 6th.

Humana Trading Down 1.7 %

NYSE:HUM opened at $290.52 on Thursday. Humana has a 12-month low of $213.31 and a 12-month high of $406.46. The firm has a market capitalization of $34.98 billion, a P/E ratio of 25.73, a P/E/G ratio of 2.21 and a beta of 0.56. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The business has a 50 day simple moving average of $275.13 and a 200 day simple moving average of $299.72.

Insider Transactions at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.29% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Pinnacle Wealth Management Advisory Group LLC raised its position in Humana by 3.6% during the fourth quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider’s stock valued at $272,000 after buying an additional 37 shares during the period. Atlas Brown Inc. raised its position in Humana by 0.6% during the fourth quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider’s stock valued at $1,611,000 after buying an additional 38 shares during the period. Moors & Cabot Inc. raised its position in Humana by 2.5% during the third quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock valued at $519,000 after buying an additional 40 shares during the period. Mather Group LLC. raised its position in Humana by 21.0% during the fourth quarter. Mather Group LLC. now owns 236 shares of the insurance provider’s stock valued at $60,000 after buying an additional 41 shares during the period. Finally, Capital Advisors Ltd. LLC raised its position in Humana by 26.1% during the fourth quarter. Capital Advisors Ltd. LLC now owns 208 shares of the insurance provider’s stock valued at $53,000 after buying an additional 43 shares during the period. 92.38% of the stock is owned by institutional investors and hedge funds.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.